VACCINATIONS
Understanding RSV and Its Impact on Infants
Respiratory Syncytial Virus (RSV) is a common virus that infects the respiratory tract, leading to illnesses ranging from mild cold-like symptoms to severe respiratory conditions such as bronchiolitis and pneumonia. Infants, especially those under six months, are particularly vulnerable to severe RSV infections, which can result in hospitalization.
Current Recommendations in Germany - Protecting Your Newborn with Passive Immunization
To safeguard newborns and infants during their first RSV season, STIKO recommends passive immunization with a monoclonal antibody called Nirsevimab (brand name: Beyfortus). This single-dose injection provides immediate protection by supplying antibodies that help prevent severe RSV-related illnesses.
In Germany, the Standing Committee on Vaccination (STIKO) has evaluated the available data on RSV vaccination during pregnancy. As of now, STIKO does not recommend RSV vaccination for pregnant individuals due to insufficient data regarding its efficacy and safety. Nonetheless, in August 2023, the European Union approved the RSV vaccine Abrysvo (Pfizer) for use during pregnancy. Despite this approval, STIKO has withheld its recommendation pending further evidence.
Timing of Administration
Infants Born Between April and September: These infants should receive the RSV-Immunisation in the autumn, ideally between September and November, before the onset of the RSV season.
Infants Born During the RSV Season (October to March): It is recommended that these newborns receive the RSV-Immunisation shortly after birth to ensure protection during their first months of life.
Safety and Efficacy
Clinical studies have demonstrated that Nirsevimab is effective in reducing the risk of severe RSV infections in infants. The safety profile is favorable, with no major hypersensitivity reactions reported.
Conclusion
Protecting infants from RSV is crucial, given the potential severity of the infection in early life. While maternal vaccination is not currently recommended in Germany, passive immunization offers an effective alternative to safeguard infants during their most vulnerable period.
_____________________________________________________________________________
Resource:
https://www.rki.de/SharedDocs/FAQ/Impfen/RSV-Prophylaxe/Empfehlung/FAQ_Liste_Empfehlung.html?
https://www.rki.de/SharedDocs/FAQ/Impfen/RSV-Prophylaxe/FAQ_Liste_gesamt.html?
https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2024/26/Art_01.html?
MOST POPULAR
